By recent standards, the first quarter of 2024 has been relatively slow in terms of novel drug approvals. Only 10 new drugs were granted authorization in the first three months of the year (Table 1). This compares to 13 in the first quarter of 2023 — a figure that was equalled or bested in each subsequent quarter of last year.

The author declares no competing interests.